Compounds > perlapine
Page last updated: 2024-12-05

perlapine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

perlapine: structure; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16106
CHEMBL ID340801
CHEBI ID31983
SCHEMBL ID114768
MeSH IDM0045035

Synonyms (66)

Synonym
{11h-dibenz[b,e]azepine,} 6-(4-methyl-1-piperazinyl)-
6-(4-methylpiperazin-1-yl)-11h-benzo[c][1]benzazepine
6-(4-methyl-1-piperazinyl)-11h-dibenzo[b,e]azepine
perlapine [usan:inn:ban:jan]
perlapina [spanish]
11h-dibenz(b,e)azepine, 6-(4-methyl-1-piperazinyl)-
perlapin
brn 0434631
hf-2333 ,
6-(4-methyl-1-piperazinyl)-11h-dibenz(b,e)azepine
mp-11
perlapina [inn-spanish]
c19h21n3
hypnodin
6-(4-methyl-1-piperazinyl)morfantridin
perlapinum [inn-latin]
nsc 291840
PDSP1_000475
nsc291840
aw-14'2333
11h-dibenz[b, 6-(4-methyl-1-piperazinyl)-
nsc-291840
6-(4-methyl-1-piperazinyl)morphanthridine
wln: t c676 in bhj j- at6n dntj d1
aw 14'2333
1977-11-3
morphanthridine, 6-(4-methyl-1-piperazinyl)-
perlapine
D01438
hypnodin (tn)
perlapine (jan/usan/inn)
PDSP2_000473
L001286
CHEMBL340801 ,
aw-142333
aw 142333
6-(4-methyl-piperazin-1-yl)-11h-dibenzo[b,e]azepine
bdbm50102325
NCGC00182979-01
4n8ujj27im ,
perlapinum
unii-4n8ujj27im
perlapina
dtxsid1048758 ,
dtxcid8028684
cas-1977-11-3
tox21_113222
perlapine [who-dd]
perlapine [mi]
perlapine [inn]
perlapine [jan]
perlapine [mart.]
perlapine [usan]
SCHEMBL114768
PWRPUAKXMQAFCJ-UHFFFAOYSA-N
11h-dibenz[b,e]azepine, 6-(4-methyl-1-piperazinyl)-
CHEBI:31983
6-(4-methyl-1-piperazinyl)-11h-dibenz[b,e]azepine
AKOS027470205
HB4889
6-(4-methylpiperazin-1-yl)-11h-dibenzo[b,e]azepine
NCGC00182979-02
Q27260239
10-(4-methylpiperazin-1-yl)-9-azatricyclo[9.4.0.0?,?]pentadeca-1(15),3,5,7,9,11,13-heptaene
CS-0033103
HY-110239

Research Excerpts

Actions

ExcerptReferenceRelevance
"Perlapine seems to enhance the turnover of 5-HT, whereas haloperidol reduced the 5-HT concentration."( Effects of clozapine, thioridazine, perlapine and haloperidol on the metabolism of the biogenic amines in the brain of the rat.
Asper, H; Bürki, HR; Ruch, W, 1975)		1.25

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency29.85540.000811.382244.6684AID686978
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency22.83430.000323.4451159.6830AID743065; AID743067
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)2.70000.00010.54948.4000AID64459
Histamine H4 receptorHomo sapiens (human)Ki4.78630.00060.478710.0000AID266654
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
inflammatory responseHistamine H4 receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationHistamine H4 receptorHomo sapiens (human)
biological_processHistamine H4 receptorHomo sapiens (human)
regulation of MAPK cascadeHistamine H4 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H4 receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayHistamine H4 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H4 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H4 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
histamine receptor activityHistamine H4 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H4 receptorHomo sapiens (human)
G protein-coupled acetylcholine receptor activityHistamine H4 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneHistamine H4 receptorHomo sapiens (human)
plasma membraneHistamine H4 receptorHomo sapiens (human)
dendriteHistamine H4 receptorHomo sapiens (human)
synapseHistamine H4 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID64459Inhibition of spiropiperidone binding at dopamine receptor D2 of rat.2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.
AID109054Antagonism of apomorphine induced climbing was determined in female swiss -Webster mice after (p.o.) +SKF525A administration of 20 mg/kg2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.
AID109038Antagonism of apomorphine induced climbing was determined in female swiss -Webster mice after (ip) administration of 2.5 mg/kg2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.
AID109047Antagonism of apomorphine induced climbing was determined in female swiss -Webster mice after (po) administration of 10 mg/kg2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.
AID109049Antagonism of apomorphine induced climbing was determined in female swiss -Webster mice after (po) administration of 20 mg/kg2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.
AID109037Antagonism of apomorphine induced climbing was determined in female swiss -Webster mice after (ip) administration of 10 mg/kg2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.
AID109051Antagonism of apomorphine induced climbing was determined in female swiss -Webster mice after (po) administration of 5 mg/kg2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.
AID109180Antagonism of apomorphine induced climbing was determined in female swiss -Webster mice after (p.o.) +SKF525A administration of 5 mg/kg2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.
AID109041Antagonism of apomorphine induced climbing was determined in female swiss -Webster mice after (ip) administration of 5 mg/kg2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.
AID109039Antagonism of apomorphine induced climbing was determined in female swiss -Webster mice after (ip) administration of 20 mg/kg2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.
AID109052Antagonism of apomorphine induced climbing was determined in female swiss -Webster mice after (p.o.) +SKF525A administration of 10 mg/kg2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.
AID266654Displacement of [3H]histamine from human histamine H4 receptor transfected in SK-N-MC cells2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Characterization of the histamine H4 receptor binding site. Part 1. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (50.00)18.7374
1990's0 (0.00)18.2507
2000's2 (16.67)29.6817
2010's2 (16.67)24.3611
2020's2 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.20 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
choline
[no description available]		1.9510cholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite
homovanillic acid
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.. homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.. homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.		2.3520guaiacols;
monocarboxylic acid		human metabolite;
mouse metabolite
hydroxyindoleacetic acid
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.		1.9510indole-3-acetic acidsdrug metabolite;
human metabolite;
mouse metabolite
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		1.9510organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		7.3520aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
loxapine
Loxapine: An antipsychotic agent used in SCHIZOPHRENIA.		2.6630dibenzooxazepineantipsychotic agent;
dopaminergic antagonist
nitrazepam
Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).		1.95101,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative
octopamine
Octopamine: An alpha-adrenergic sympathomimetic amine, biosynthesized from tyramine in the CNS and platelets and also in invertebrate nervous systems. It is used to treat hypotension and as a cardiotonic. The natural D(-) form is more potent than the L(+) form in producing cardiovascular adrenergic responses. It is also a neurotransmitter in some invertebrates.. octopamine : A member of the class of phenylethanolamines that is phenol which is substituted at the para- position by a 2-amino-1-hydroxyethyl group. A biogenic phenylethanolamine which has been found to act as a neurotransmitter, neurohormone or neuromodulator in invertebrates.		1.9610phenylethanolamines;
tyramines		neurotransmitter
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		1.9510barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
quetiapine
[no description available]		210dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine		adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist
thioridazine
Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.		6.9510phenothiazines;
piperidines		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
11-(4-methyl-1-piperazinyl)-5h-dibenzo(b,e)(1,4)diazepine
11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine: structure given in first source		1.9610
2-chloro-11-(4-methyl-1-piperazinyl)-5h-dibenzo(b,e)(1,4)diazepine
2-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine: structure given in first source		1.9610
chlorphenamidine
Chlorphenamidine: An acaricide used against many organophosphate and carbamate resistant pests. It acts as an uncoupling agent and monoamine oxidase inhibitor.		1.9610
1-(3-chloro-5-benzo[b][1]benzoxepinyl)-4-methylpiperazine
[no description available]		2.0310N-alkylpiperazine;
organic heterotricyclic compound
jnj 7777120
1-((5-chloro-1H-indol-2-yl)carbonyl)-4-methylpiperazine: an H4 receptor antagonist; structure in first source		2.0310
clozapine
Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.		3.2460benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
clozapine n-oxide
clozapine N-oxide: structure given in first source		2.1110dibenzodiazepine
ConditionIndicatedRelationship StrengthStudiesTrials
Dyskinesia, Medication-Induced
[description not available]		0210
Dyskinesia, Drug-Induced
Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)		0210
Atherosclerotic Parkinsonism
[description not available]		01.9510
Parkinson Disease, Secondary
Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)		01.9510